[Immunological approach and surgical treatment of cancer].
It is first mentioned that there is a method of evaluation for the effect on immunochemotherapy as an adjuvant and supporting therapy to surgery. The availability of clinical immunotherapy with surgical treatment was studied by using some prospectively randomized trials. The results were summarized as follows; A combined modality therapy of nonspecific and host mediate immunotherapy and chemotherapy as an adjuvant to surgery was effective on long survival, and the therapy had simultaneously a protective effect of toxicity based on some chemotherapeutic agents. The therapy was effective on the patients who had rather immunologically high response such as curatively or non-curatively resected case than those of nonresectable case. In some combination, combined modality therapy may have not effect, so it should be used under paying attention to the points that are type and dose of agents, timing and interval of administration, and combination method of surgical, chemical and immunological treatments.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000601:surgery*; D005641:Tegafur / Q000008:administration & dosage
D008937:Mitomycins; D005641:Tegafur; D010844:Picibanil; D016685:Mitomycin; D005472:Fluorouracil